NK NantKwest Inc

Dr. Patrick Soon-Shiong keynotes on breakthroughs in immuno-oncology including development of Genomic Proteomic Sequencing test for cancer (GPS Cancer)

NantWorks, LLC, NantKwest (Nasdaq: NK), and NantHealth, LLC today announced the scheduled discussion topics at the eighth annual Cancer Center Business Summit, a premier oncology event with this year’s theme, “Oncology Care Transformation: What’s Working and What Lies Ahead.” The Cancer Center Business Summit will take place on February 24-25, 2016 at the JW Marriott Phoenix Desert Ridge Hotel in Phoenix, Arizona.

Patrick Soon-Shiong, M.D., founder and CEO of NantWorks, and leader of the Cancer MoonShot 2020 program, will deliver the luncheon keynote addressing breakthroughs in immuno-oncology, the vision behind Cancer MoonShot 2020, and the development of Genomic Proteomic Sequencing (GPS) testing for cancer. GPS Cancer™ is a first-of-its-kind, comprehensive multiomic-based test in development at NantOmics, LLC. The GPS Cancer test integrates whole genome (DNA), whole transcriptome (RNA), quantitative proteomics and predictive analytics resulting in a comprehensive molecular profile of a patient’s cancer to inform personalized treatment options. GPS Cancer is expected to launch in Q2 2016.

Carla Balch, senior vice president clinical strategy at NantKwest, and Gary Palmer, M.D., chief medical officer of NantHealth, will also participate in panel discussions to address the future of care delivery and clinical trials specific to oncology. During these sessions, attendees will learn more about the GPS Cancer test and how they can engage and participate in Cancer MoonShot 2020 as the program advances the potential of combination immunotherapies as the next-generation standard of cancer care.

 

NantWorks, NantKwest and NantHealth Participation at Cancer Center Business Summit 2016

 

WHO:

     

Patrick Soon-Shiong M.D., FRCS(C), FACS, chairman and chief executive officer,NantWorks

WHAT:

Luncheon Keynote Address: “Breakthroughs in Immuno-Oncology: ActivatingNatural Killer Cells to Outsmart Cancer”

WHEN:

Wednesday, February 24, 12:30-2 p.m. MST  

WHO:

Carla Balch, senior vice president clinical strategy, NantKwest

WHAT:

Track B Panel Discussion: “Consumer-driven Care Delivery”

WHEN:

Wednesday, February 24, 2-3 p.m. MST  

WHO:

Gary Palmer, M.D., J.D., MBA, chief medical officer, NantHealth and Carla Balch,senior vice president clinical strategy, NantKwest

WHAT:

Track B Panel Discussion: “Research – Clinical Trials as Part of the Service Line”

WHEN:

Thursday, February 25, 1:45-2:45 p.m. MST

WHERE:

Cancer Center Business Summit

JW Marriott Phoenix Desert Ridge Hotel 5350 East Marriott Drive Phoenix, AZ 85054

Register Here

 

About NantWorks

NantWorks, LLC, is the umbrella organization for an ecosystem of companies committed to the convergence of 21st century innovative platforms to transform how we work, live and play: NantHealth, NantOmics, NantBioScience, NantCell, NantKwest, NantPharma, NantMobile, NantStudio, NantCapital and NantCloud. Fact-based and solution driven, each of NantWorks’ division companies operates at the intersection of innovation and infrastructure. For more information please visit www.nantworks.com and follow Dr. Soon-Shiong on Twitter @solvehealthcare.

About NantKwest Inc.

NantKwest (Nasdaq:NK) is a pioneering, next generation, clinical-stage immunotherapy company focused on harnessing the unique power of our immune system using natural killer (NK) cells to treat cancer, infectious diseases and inflammatory diseases. NK cells are the body’s first line of defense due to the innate ability of NK cells to rapidly identify and destroy cells under stress, such as cancer or virally-infected cells.

NantKwest’s unique NK cell-based platform, with the capacity to grow active killer cells as a biological cancer therapy, has been designed to induce cell death against cancer or infected cells by three different modes of action: (1) Direct killing using activated NK cells (aNK) that release toxic granules directly into the cell through cell to cell contact, (2) Antibody-mediated killing using haNKs, which are NK cells engineered to incorporate a high affinity receptor that binds to an administered antibody, enhancing the cancer cell killing effect of that antibody, and (3) Targeted activated killing using taNKs, which are NK cells engineered to incorporate chimeric antigen receptors (CARs) to target tumor-specific antigens found on the surface of cancer cells.

Our aNK, haNK and taNK platform addresses certain limitations of T cell therapies including the reduction of risk of serious "cytokine storms" reported after T cell therapy. As an “off-the-shelf” therapy, NantKwest's NK cells do not rely on a patient’s own often compromised immune system. In Phase 1 clinical trials in patients with late stage cancer, NantKwest's NK cells have been successfully administered as an outpatient infusion therapy without any reported severe side effects, even at doses of 10 billion cells.

By leveraging an integrated and extensive genomics and transcriptomics discovery and development engine, together with a pipeline of multiple, clinical-stage, immuno-oncology programs that include a Phase 2 trial for a rare form of melanoma and the planned initiation of a clinical trial of NK cells targeted to breast cancer, we believe NantKwest is uniquely positioned to be the premier immunotherapy company and transform medicine by delivering living drugs in a bag and bringing novel NK cell-based therapies to routine clinical care. For more information please visit http://www.nantkwest.com and follow Dr. Soon-Shiong on Twitter @solvehealthcare.

About NantHealth

NantHealth, LLC, a member of the NantWorks ecosystem of companies, is a transformational healthcare IT company converging science and technology through a single integrated clinical platform, to provide actionable health information at the point of care, in the time of need, anywhere, anytime. NantHealth works to transform clinical delivery with actionable clinical intelligence at the moment of decision, enabling clinical discovery through real-time machine learning systems. The company’s technology empowers physicians, patients, payers and researchers to transcend genomics into the world of proteomics and the traditional barriers of today’s healthcare system. By converging molecular science, computer science and big data technology the Nant Service Oriented Operating System (NantOS) platform empowers physicians, patients, and payers to coordinate best care, monitor outcomes and control cost in real time. This is the first operating system of its kind in healthcare that is based on supply chain principles and grid service oriented architecture and integrates the knowledge base with the delivery system and the payment system, enabling 21st century coordinated care at a lower cost. For more information please visit www.nanthealth.com and follow Dr. Soon-Shiong on Twitter @solvehealthcare.

View source version on businesswire.com: http://www.businesswire.com/news/home/20160222005761/en/

NantWorksJen Hodson, 562-397-3639jhodson@nantworks.com